Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice
Event: ESC Congress 2025
Topic: Cardiovascular Pharmacotherapy
Session: Late-Breaking Clinical Science: cardiometabolic medicine
